LISCure Biosciences Fact Sheet

## **Company Overview**

**LISC**ure



Single strains of microbes selected for defined pharmacological properties

Data driven development across oncology, CNS, immunology, and liver diseases

Goal-oriented integration of R&D and business development expertise

#### **Bacterial Approaches**



Single strain of naturally food-derived microbiome profiles will most benefit in terms of tolerability and safety. Also, it is much less complicated to assign cause and effect associations with single strains rather than multi strains.

Single strain products are more likely to contain clinical doses than multistrains due to practical constraint, such as cost and dosage size required.

Although LISCure prioritizes single strain approach with each programs, there are still opportunities to explore multiple strain approaches by mixing-and-matching given that our programs show high potencies in each disease model.

# **Program Highlights**

Our oncology programs including **LB-100** and **LB-200** could suppress the tumor growth significantly in variable types of tumor xenograft models with single administration; **LB-300** showed significant reduction in tumor volume in skin melanoma model.

Our CNS programs, **LB-400** improved motor dysfunction and grip strength in MPTP mice model; **LB-500** reduced motor dysfunction, depressive symptoms, and poor concentration in mice model.

**LB-600** improved arthritic symptoms without loss of body weight of CIA mice and showed statistically significant inhibition effects on auto-antibody and inflammatory cytokine level in mice model.

**LB-700** and **LB-800** showed significant reduction in body weight and liver weight which will provide benefits in NAFLD and NASH. The program also improved lipid profiles through inhibition of lipogenesis and showed anti-inflammatory/anti-fibrotic effects through suppression of inflammatory/fibrotic gene expression.

### **Global Facts**



The number of microbiome-related papers has increased nearly 100 times in 2016, 85% of which are on human microbiome.



The global market for human microbiomebased drugs should reach a market size of nearly \$9.4 billion by 2024.

# **Pipeline of Live Biotherapeutic Product Candidates**

Indication	Discovery	In Vitro Validation	In Vivo Efficacy	PK/PD/Tox	IND	Phase 1
Oncology						
Colorectal Cancer			Present		2021 1H	2021 2H
Non-small Cell Lung Cancer (NSCLC)			Present		2021 1H	2021 2H
Melanoma		Present		2021 1H	2021 2H	
Solid Tumors		Present		2021 1H	2021 2H	
Colorectal Cancer			Present		2021 1H	2021 2H
Colorectal Cancer			Present		2021 1H	2021 2H
Melanoma			Present		2021 1H	2021 2H
Solid Tumors		Present		2021 1H	2021 2H	
Central Nervous System Disorder						
Parkinson's Disease			Present		2021 2H	2022 1H
Major Depressive Disorder			Present		2021 2H	2022 1H
Immunology						
Rheumatoid Arthritis			Present		2021 2H	2022 1H
Liver Disease						
Non-alcoholic Steatohepatitis (NASH)			Present		2022 1H	2022 2H
NASH			Present		2022 1H	2022 2H
	Indication Colorectal Cancer Non-small Cell Lung Cancer (NSCLC) Melanoma Solid Tumors Colorectal Cancer Colorectal Cancer Melanoma Solid Tumors ystem Disorder Parkinson's Disease Major Depressive Disorder Rheumatoid Arthritis Non-alcoholic Steatohepatitis (NASH) NASH	IndicationDiscoveryColorectal CancerImage: Colorectal CancerNon-small Cell Lung CancerImage: Colorectal CancerSolid TumorsImage: Colorectal CancerColorectal CancerImage: Colorectal CancerMelanomaImage: Colorectal CancerSolid TumorsImage: Colorectal CancerMelanomaImage: Colorectal CancerSolid TumorsImage: Colorectal CancerMelanomaImage: Colorectal CancerSolid TumorsImage: Colorectal CancerYstem DisorderImage: Colorectal CancerParkinson's DiseaseImage: Colorectal CancerMajor Depressive DisorderImage: Colorectal CancerRheumatoid ArthritisImage: Colorectal CancerNon-alcoholicImage: Colorectal CancerNaSHImage: Colorectal Cancer	IndicationDiscoveryIn Vitro ValidationColorectal CancerNon-small Cell Lung Cancer(NSCLC)MelanomaPresentSolid TumorsPresentColorectal CancerColorectal CancerMelanomaSolid TumorsPresentYstem DisorderParkinson's DiseaseMajor Depressive DisorderRheumatoid ArthritisNon-alcoholic Steatohepatitis (NASH)NASH	IndicationDiscoveryIn Vitro ValidationIn Vivo EfficacyColorectal CancerPresentPresentNon-small Cell Lung Cancer (NSCLC)PresentPresentMelanomaPresentPresentSolid TumorsPresentPresentColorectal CancerPresentPresentColorectal CancerPresentPresentSolid TumorsPresentPresentSolid TumorsPresentPresentMelanomaPresentPresentSolid TumorsPresentPresentSolid TumorsPresentPresentSolid TumorsPresentPresentSolid TumorsPresentPresentMajor Depressive DisorderPresentPresentRheumatoid ArthritisPresentPresentNon-alcoholic Steatohepatitis (NASH)PresentPresentNASHPresentPresent	IndicationDiscoveryIn Vitro ValidationIn Vivo EfficacyPK/PD/ToxColorectal CancerPresentNon-small Cell Lung Cancer (NSCLC)Present2021 1HMelanomaPresent2021 1HSolid TumorsPresent2021 1HColorectal CancerPresent2021 1HColorectal CancerPresent2021 1HColorectal CancerPresentMelanomaPresentSolid TumorsPresent2021 1HYstem DisorderPresentParkinson's DiseasePresentMajor Depressive DisorderPresentRheumatoid ArthritisPresentNon-alcoholic Steatohepatitis (NASH)PresentNASHPresent	IndicationDiscoveryIn Vitro ValidationIn Vivo EfficacyPK/PD/ToxINDColorectal CancerPresent2021 1HNon-small Cell Lung Cancer (NSCLC)PresentPresent2021 1HMelanomaPresent2021 1H2021 2HSolid TumorsPresent2021 1H2021 2HColorectal CancerPresent2021 1H2021 2HColorectal CancerPresent2021 1H2021 2HColorectal CancerPresent2021 1H2021 1HSolid TumorsPresent2021 1H2021 2HSolid TumorsPresent2021 1H2021 2HSolid TumorsPresent2021 1H2021 2HMelanomaPresent2021 1H2021 2HSolid TumorsPresent2021 1H2021 2HYstem DisorderPresent2021 2H2021 2HParkinson's DiseasePresent2021 2H2021 2HMajor Depressive DisorderPresent2021 2HRheumatoid ArthritisPresent2021 2HNon-alcoholic Steatohepatitis (NASH)Present2022 1HNASHPresent2022 1H



Contact

Business Development LISCure Biosciences 626, Gangnam-daero, Gangnam-gu, Seoul, 06035 +82 2 3443 1800 | BD@liscure.bio